Related Experiment Video

Updated: Oct 17, 2026

A β-glucuronidase (GUS) Based Cell Death Assay
07:35

A β-glucuronidase (GUS) Based Cell Death Assay

Published on: May 6, 2011

Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy

D Weyel1, H H Sedlacek, R Müller

  • 1Institute of Molecular Biology and Tumor Research (IMT), Philipps-University Marburg, Germany.

Gene Therapy
|March 1, 2000
PubMed

Insights

This study introduces a novel gene therapy approach using secreted beta-glucuronidase to convert a prodrug into a potent cancer drug, enhancing the bystander effect for superior tumor cell killing compared to traditional chemotherapy.

Area of Science:

  • Oncology
  • Gene Therapy
  • Biochemistry

Background:

  • Low transduction efficiency of current gene therapy vectors limits efficacy.
  • The bystander effect, where therapeutic genes kill neighboring cells, is a key strategy.
  • Extracellular prodrug conversion offers a potential improvement for the bystander effect.

Purpose of the Study:

  • To develop an extracellular cytotoxic effector system using secreted human beta-glucuronidase (s-betaGluc).
  • To evaluate the conversion of a doxorubicin prodrug (HMR 1826) to a cytotoxic drug.
  • To assess the efficacy of this system in vitro and in vivo, focusing on the bystander effect.

Main Methods:

  • Transduction of tumor cells with a gene encoding secreted human beta-glucuronidase (s-betaGluc).
  • Administration of a glucuronidated doxorubicin prodrug (HMR 1826).
  • Assessment of HMR 1826 conversion to doxorubicin and subsequent cell killing in cell culture and in vivo models.

Main Results:

  • s-betaGluc-transduced cells efficiently converted HMR 1826 to cytotoxic doxorubicin.
  • Generated doxorubicin was taken up by both transduced and non-transduced tumor cells.
  • The s-betaGluc/HMR 1826 system demonstrated potent tumor cell killing via a strong bystander effect, outperforming conventional doxorubicin chemotherapy.

Conclusions:

  • Extracellular conversion of a prodrug by secreted enzymes can enhance gene therapy efficacy.
  • This novel gene therapy strategy shows significant promise, offering advantages over traditional chemotherapy.
  • The developed system effectively utilizes the bystander effect for improved tumor treatment.

More Related Videos

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

Tracing Gene Expression Through Detection of β-galactosidase Activity in Whole Mouse Embryos08:42

Tracing Gene Expression Through Detection of β-galactosidase Activity in Whole Mouse Embryos

Published on: June 26, 2018

Related Concept Videos

Gene Therapy01:22

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
In-vitro Mutagenesis (Gene Knockouts)02:29

In-vitro Mutagenesis (Gene Knockouts)

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.